Retrophin, Inc. (RTRX)

19.33
0.38 1.93
NASDAQ
Prev Close 19.71
Open 19.85
Day Low/High 19.30 / 19.85
52 Wk Low/High 19.77 / 33.00
Volume 269.40K
Exchange NASDAQ
Shares Outstanding 41.44B
Market Cap 824.18M
Div & Yield N.A. (N.A)

Latest News

First Week Of RTRX September 20th Options Trading

First Week Of RTRX September 20th Options Trading

Investors in Retrophin, Inc. saw new options begin trading this week, for the September 20th expiration.

Interesting RTRX Put Options For November 16th

Interesting RTRX Put Options For November 16th

Investors in Retrophin, Inc. saw new options begin trading this week, for the November 16th expiration.

Robbins Arroyo LLP Is Investigating The Officers And Directors Of Retrophin, Inc. (RTRX) On Behalf Of Shareholders

Robbins Arroyo LLP Is Investigating The Officers And Directors Of Retrophin, Inc. (RTRX) On Behalf Of Shareholders

Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Retrophin, Inc.

First Week Of August 17th Options Trading For Retrophin (RTRX)

First Week Of August 17th Options Trading For Retrophin (RTRX)

Investors in Retrophin, Inc. saw new options begin trading this week, for the August 17th expiration.

Commit To Buy Retrophin At $12.50, Earn 6.4% Annualized Using Options

Investors eyeing a purchase of Retrophin, Inc. shares, but tentative about paying the going market price of $21.42/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Notable Two Hundred Day Moving Average Cross - RTRX

Notable Two Hundred Day Moving Average Cross - RTRX

In trading on Monday, shares of Retrophin, Inc. crossed below their 200 day moving average of $22.55, changing hands as low as $22.50 per share.

Retrophin Provides Corporate Update And 2018 Outlook

Retrophin Provides Corporate Update And 2018 Outlook

Preliminary full-year 2017 revenue of approximately $155 million

Retrophin Announces Presentation Of New Data From Physician-Initiated Treatment With Fosmetpantotenate At The Child Neurology Society's 26th Annual Meeting

Retrophin Announces Presentation Of New Data From Physician-Initiated Treatment With Fosmetpantotenate At The Child Neurology Society's 26th Annual Meeting

Patient with PKAN showed persistent improvement in function over 30-month period of treatment with fosmetpantotenate

Martin Shkreli Was Just Convicted on 3 Counts of Securities Fraud

Martin Shkreli Was Just Convicted on 3 Counts of Securities Fraud

"Pharma bro" Martin Shkreli was found guilty on three of eight counts of securities fraud.

Retrophin Commences Patient Dosing In International, Registrational Phase 3 Trial Of RE-024 In PKAN

Retrophin Commences Patient Dosing In International, Registrational Phase 3 Trial Of RE-024 In PKAN

FORT Study to assess efficacy and safety of novel replacement therapy

TheStreet Quant Rating: D+ (Sell)